Compare WIA & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | CVRX |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 171.7M |
| IPO Year | N/A | 2021 |
| Metric | WIA | CVRX |
|---|---|---|
| Price | $7.99 | $9.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.20 |
| AVG Volume (30 Days) | 56.1K | ★ 259.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $16.65 |
| Revenue Next Year | N/A | $18.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $7.97 | $4.37 |
| 52 Week High | $8.54 | $13.15 |
| Indicator | WIA | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 67.61 |
| Support Level | N/A | $8.42 |
| Resistance Level | $8.31 | $10.39 |
| Average True Range (ATR) | 0.06 | 0.57 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 17.02 | 91.29 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.